| Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis. | |
| | |
MedLine Citation:
|
PMID: 20217447 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Efficacy and safety of irinotecan and cisplatin administration every 2 weeks (biweekly regimen) or 4 weeks (4-weekly regimen) in patients with pretreated unresectable or recurrent gastric cancer was retrospectively evaluated. METHODS: Study patients comprised two cohorts: cohort 1, consisting of 31 patients received chemotherapy on a 4-weekly regimen; and cohort 2, consisting of 32 patients received chemotherapy on a biweekly regimen. In cohort 1, patients received irinotecan (70 mg/m(2)) on days 1 and 15 and cisplatin (80 mg/m(2)) on day 1 every 4 weeks; in cohort 2, patients received irinotecan (60 mg/m(2)) on day 1 and cisplatin (30 mg/m(2)) on day 1 every 2 weeks. RESULTS: Response rates were for cohorts 1 and 2 were 26% (7/27) and 28% (7/25) in patients with measurable lesions, median progression-free survivals were 3.5 and 4.3 months, and median survival times after irinotecan and cisplatin initiation were 9.5 and 10.1 months, respectively. The incidence of grades 3 and 4 hematological toxicities in cohorts 1 and 2 were 74% and 44% for leukopenia, 81% and 53% for neutropenia, and 45% and 28% for anemia, respectively. Incidences of grades 3 and 4 nonhematological toxicities were 23% and 12% for nausea, 23% and 9% for vomiting, 19% and 12% for anorexia, and 6% and 6% for febrile neutropenia, respectively. CONCLUSION: Irinotecan plus cisplatin chemotherapy administered on a biweekly regimen was comparable in efficacy to a 4-weekly regimen and might be more feasible than the 4-weekly regimen. |
| | |
Authors:
|
Takeshi Sakamoto; Hirofumi Yasui; Narikazu Boku; Yusuke Onozawa; Shuichi Hironaka; Akira Fukutomi; Kentaro Yamazaki; Keisei Taku; Nozomu Machida; Akiko Todaka; Hideharu Tomita; Takahiro Tsushima; Hiroya Taniguchi; Satoshi Hamauchi |
Related Documents
:
|
15784807 - Successful desensitization to oxaliplatin. 8996157 - Phase ii study of irinotecan and etoposide in patients with metastatic non-small-cell l... 17630037 - Different strategies of sequential and combination chemotherapy for patients with poor ... 20016807 - Vascular endothelial growth factor plus epidermal growth factor receptor dual targeted ... 12451477 - Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelo... 9784317 - The pre- and postoperative value of endocervical curettage in the detection of cervical... |
Publication Detail:
|
Type: Comparative Study; Journal Article Date: 2010-03-10 |
Journal Detail:
|
Title: International journal of clinical oncology Volume: 15 ISSN: 1437-7772 ISO Abbreviation: Int. J. Clin. Oncol. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-06-14 Completed Date: 2010-09-27 Revised Date: 2012-12-13 |
Medline Journal Info:
|
Nlm Unique ID: 9616295 Medline TA: Int J Clin Oncol Country: Japan |
Other Details:
|
Languages: eng Pagination: 287-93 Citation Subset: IM |
Affiliation:
|
Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. t.sakamoto@scchr.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
drug therapy*,
mortality,
pathology,
radiography Adult Aged Antineoplastic Agents, Phytogenic / administration & dosage Antineoplastic Combined Chemotherapy Protocols / administration & dosage*, adverse effects Camptothecin / administration & dosage, analogs & derivatives Cisplatin / administration & dosage Disease-Free Survival Drug Administration Schedule Female Humans Kaplan-Meier Estimate Male Middle Aged Neoplasm Recurrence, Local / drug therapy*, mortality Retrospective Studies Stomach Neoplasms / drug therapy*, mortality, pathology, radiography Time Factors Tomography, X-Ray Computed Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Phytogenic; 15663-27-1/Cisplatin; 7673326042/irinotecan; 7689-03-4/Camptothecin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dots are not clots: the over-diagnosis and over-treatment of PE.
Next Document: Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient ...